Priya Singhal
Executive VP & Head of DevelopmentDr. Priya Singhal, M.D. M.P.H., served as Interim Chief Medical Officer at Biogen Inc. since February 2024 and served as Senior Vice President since 2020 until January 2023 and serves as its Executive Vice President from January 2023. She served as Head of Global Safety & Regulatory Sciences at Biogen Inc since 2020 and served as its Interim Head Development since December 31, 2021 and served as its Interim Head of Research since December 31, 2021 until October 02, 2023 and serves as its Head of Development. She was Interim Head of Global Safety and Regulatory Sciences at Biogen Inc. until June 2023. She joined Biogen Inc. since 2020. Dr. Singhal had been Head of Research and Development at Zafgen, Inc. since March 04, 2019 until January 31, 2020. Dr. Singhal has more than a decade of experience as a senior drug development executive and many experience as a clinician and leads and oversees Zafgen's research, clinical and manufacturing strategy and implementation. She also serves as a key Member of the executive team supporting overall business strategy. Dr. Singhal joins Zafgen from Biogen, where she was concurrently the Senior Vice President and the Global Head of Safety and Benefit Risk Management (SABR) and the Interim Global Co-lead and Senior Vice President of Global Development. During her tenure at Biogen, Dr. Singhal led the worldwide benefit-risk strategy for the Biogen portfolio as well as for the filings and approvals of six products, including Tecfidera and Spinraza. She also contributed to Biogen's overall R&D strategy and drug development plans, Chaired safety governance for the entire portfolio and led numerous successful portfolio and product interactions with regulators worldwide. Prior to Biogen, Dr. Singhal held roles of increasing seniority at Vertex Pharmaceuticals, including VP, Medical Affairs, where she led strategy and educational efforts across all Vertex programs including the company's hepatitis C (HCV) and cystic fibrosis portfolios. Previously, Dr. Singhal also led benefit-risk for Velcade and two compounds in the development portfolio at Millennium Pharmaceuticals. Dr. Singhal earned her M.P.H. in International Health at Harvard School of Public Health and M.D. (internal medicine) from the University of Mumbai. She is a frequent, invited speaker at pharmaceutical and biotechnology conferences and is actively engaged in national and international educational programs about drug development.
Positions
- Company NameBiogen Inc.Stock CodeBIIBPositionExecutive VP & Head of DevelopmentColleagues
- CAChristopher A. ViehbacherPresident, CEO & Director
- MCMaria C. FreireIndependent Chair of the Board
- RCRobin C. KramerExecutive VP & CFO
- NMNicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology
- SGSean GodboutVP, Chief Accounting Officer & Global Corporate Controller
- JBJesus B. MantasIndependent Director
- MDMonish D. PatolawalaIndependent Director
- EKEric K. RowinskyIndependent Director
